We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
+87.55%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$5.13B
AUM Growth
+$1.97B
(+62%)
Cap. Flow
+$788M
Cap. Flow
% of AUM
15.36%
Top 10 Holdings %
Top 10 Hldgs %
55.31%
Holding
66
New
18
Increased
9
Reduced
12
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
+$391M |
| 2 |
Novavax
NVAX
|
+$182M |
| 3 |
Vaxcyte
PCVX
|
+$177M |
| 4 |
Legend Biotech
LEGN
|
+$97M |
| 5 |
MacroGenics
MGNX
|
+$79.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$233M |
| 2 |
Exelixis
EXEL
|
+$77.9M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$44.1M |
| 4 |
Gilead Sciences
GILD
|
+$41M |
| 5 |
Relmada Therapeutics
RLMD
|
+$22.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.84% |
| 2 | Miscellaneous | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$15.8B
| $727M | 14.17% |
4,914,955
| – | – |
|
|
FMTX
2
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $419M | 8.16% |
+9,011,651
| New | +$391M |
|
|
3
Novavax
NVAX
$1.52B
| $397M | 7.73% |
+4,758,833
| New | +$182M |
|
|
CCXI
4
DELISTED
ChemoCentryx, Inc.
CCXI
| $278M | 5.41% |
4,826,910
+650,000
| +16% | +$35.4M |
|
5
TG Therapeutics
TGTX
$8.12B
| $249M | 4.85% |
12,788,457
+2,401,046
| +23% | +$38.7M |
|
|
6
Vaxcyte
PCVX
$8.81B
| $174M | 3.38% |
+5,489,181
| New | +$177M |
|
7
Axsome Therapeutics
AXSM
$10.7B
| $167M | 3.26% |
2,035,132
+131,038
| +7% | +$10.1M |
|
|
ADVM
8
DELISTED
Adverum Biotechnologies
ADVM
| $163M | 3.17% |
780,164
+52,893
| +7% | +$9.37M |
|
|
STSA
9
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $135M | 2.62% |
4,681,858
| – | – |
|
|
ADAP
10
DELISTED
Adaptimmune Therapeutics
ADAP
| $131M | 2.55% |
13,052,464
+510,576
| +4% | +$3.21M |
|
|
11
MacroGenics
MGNX
$257M
| $128M | 2.49% |
+4,584,652
| New | +$79.6M |
|
12
Phathom Pharmaceuticals
PHAT
$660M
| $126M | 2.45% |
3,825,008
+117,600
| +3% | +$4.52M |
|
13
Arvinas
ARVN
$540M
| $123M | 2.4% |
3,672,872
| – | – |
|
14
Rhythm Pharmaceuticals
RYTM
$6.66B
| $116M | 2.26% |
5,210,088
-212,224
| -4% | -$4.14M |
|
15
KALA BIO
KALA
$9.82M
| $114M | 2.23% |
4,354
| – | – |
|
16
Black Diamond Therapeutics
BDTX
$113M
| $109M | 2.13% |
2,589,904
| – | – |
|
|
17
Legend Biotech
LEGN
$3.44B
| $106M | 2.06% |
+2,481,942
| New | +$97M |
|
|
EIDX
18
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $103M | 2.01% |
2,162,671
| – | – |
|
19
Alector
ALEC
$228M
| $101M | 1.97% |
4,127,348
| – | – |
|
|
ZGNX
20
DELISTED
Zogenix, Inc.
ZGNX
| $99.3M | 1.94% |
3,677,424
-1,598,114
| -30% | -$44.1M |
|
21
Travere Therapeutics
TVTX
$5.89B
| $94.6M | 1.84% |
4,635,687
+469,234
| +11% | +$7.47M |
|
|
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $84.2M | 1.64% |
2,531,445
| – | – |
|
23
Wave Life Sciences
WVE
$879M
| $80.9M | 1.58% |
7,775,207
| – | – |
|
|
IGMS
24
DELISTED
IGM Biosciences
IGMS
| $71.7M | 1.4% |
982,723
| – | – |
|
25
Keros Therapeutics
KROS
$221M
| $70.3M | 1.37% |
+1,875,000
| New | +$57.8M |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, RA Capital Management held 66 positions worth $5.13B, up 62% from $3.17B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
RA Capital Management deployed $788M of net new capital in Q2 2020, opening 18 new positions and adding to 9 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 9,011,651 shares worth $419M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Zogenix, Inc., an estimated $44.1M trimmed.
- RA Capital Management's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 9,011,651 shares worth $419M.
- RA Capital Management added most to TG Therapeutics in Q2 2020, an estimated $38.7M increase.
- RA Capital Management's biggest Q2 2020 reduction was Zogenix, Inc., cutting an estimated $44.1M.
- RA Capital Management fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $233M.
- RA Capital Management's ten largest holdings make up 55% of its $5.13B portfolio in Q2 2020.
- RA Capital Management opened 18 new positions and closed 9 in Q2 2020.
- RA Capital Management's portfolio value rose 62% quarter-over-quarter to $5.13B.
Based on RA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.